Hydrodynamic-based microfluidic platforms enable single-cell arraying and analysis over time. Despite the advantages of established microfluidic systems, long-term analysis and proliferation of cells selected in such devices require off-chip recovery of cells as well as an investigation of on-chip analysis on cell phenotype, requirements still largely unmet. Here, we introduce a device for single-cell isolation, selective retrieval and off-chip recovery. To this end, singularly addressable three-dimensional electrodes are embedded within a microfluidic channel, allowing the selective release of single cells from their trapping site through application of a negative dielectrophoretic (DEP) force. Selective capture and release are carried out in standard culture medium and cells can be subsequently mitigated towards a recovery well using micro-engineered hybrid SU-8/PDMS pneumatic valves. Importantly, transcriptional analysis of recovered cells revealed only marginal alteration of their molecular profile upon DEP application, underscored by minor transcriptional changes induced upon injection into the microfluidic device. Therefore, the established microfluidic system combining targeted DEP manipulation with downstream hydrodynamic coordination of single cells provides a powerful means to handle and manipulate individual cells within one device.
The simplicity of homogeneous immunoassays makes them suitable for diagnostics of acute conditions. Indeed, the absence of washing steps reduces the binding reaction duration and favors a rapid and compact device, a critical asset for patients experiencing life-threatening diseases. In order to maximize analytical performance, standard systems employed in clinical laboratories rely largely on the use of high surface-to-volume ratio suspended moieties, such as microbeads, which provide at the same time a fast and efficient collection of analytes from the sample and controlled aggregation of collected material for improved readout. Here, we introduce an integrated microfluidic system that can perform analyte detection on antibody-decorated beads and their accumulation in confined regions within 15 min. We employed the system to the concomitant analysis of clinical concentrations of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin C in serum, two acute kidney injury (AKI) biomarkers. To this end, high-aspect-ratio, three-dimensional electrodes were integrated within a microfluidic channel to impart a controlled trajectory to antibody-decorated microbeads through the application of dielectrophoretic (DEP) forces. Beads were efficiently retained against the fluid flow of reagents, granting an efficient on-chip analyte-to-bead binding. Electrokinetic forces specific to the beads’ size were generated in the same channel, leading differently decorated beads to different readout regions of the chip. Therefore, this microfluidic multianalyte immunoassay was demonstrated as a powerful tool for the rapid detection of acute life-threatening conditions.
7 October 2024 in Nature Reviews Electrical Engineering
Kidney diseases, whether acute or chronic, remain among the most challenging conditions to diagnose due to their complex and often asymptomatic progression. Emerging biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C (CysC) correlate with early pathogenesis and offer complementary insights into disease etiology. However, quantification of their levels, which is essential for patient staging, is available only in centralized laboratories. We present the lateral-flow microfluidic bead-based assay (LMBA), the first rapid, self-contained system for NGAL and CysC analysis. LMBA integrates a microfluidic chip with paper-based components to run automated high-resolution immunoassays in 20 min. Its modular architecture, decoupling reagent storage and flow control from assay binding and readout, offers significant design flexibility. Validated against ELISA, LMBA exhibits comparable sensitivity with an extended dynamic range, requiring only 1 μL of the original blood or urine sample prior to dilution. We applied the LMBA to neonatal mouse models of polycystic kidney disease and measured biomarker elevations consistent with cyst progression. This scalable platform supports preclinical research and holds strong potential for decentralized kidney disease diagnostics.